SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on November 13th 2024 with the purchase of 8,700 own shares at the average price of 10.
SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on November 12th 2024 with the purchase of 5,250 own shares at the average price of 10.
Sarantis Health & Care division participated for the second consecutive year in the Conference of the Piraeus Pharmaceutical Association, held on Sunday, November 3, 2024, at the iconic Zappeion Megaron.
SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on November 11th 2024 with the purchase of 7,700 own shares at the average price of 10.
SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on November 8th 2024 with the purchase of 3,500 own shares at the average price of 10.
SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on November 7th 2024 with the purchase of 1,980 own shares at the average price of 11.
SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on November 6th 2024 with the purchase of 4,822 own shares at the average price of 10.
SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on November 5th 2024 with the purchase of 6,800 own shares at the average price of 10.